Impact of pharmaceutical validation on prescribing errors in a Neonatal Intensive Care Unit.

Impact of pharmaceutical validation on prescribing errors in a Neonatal Intensive Care Unit. Randomised and controlled study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12370877

Enrollment

164

Registered

2023-11-21

Start date

2021-09-01

Completion date

Unknown

Last updated

2023-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prevention of medical errors in newborns Pregnancy and Childbirth

Interventions

During the randomised phase, patients were assigned to the intervention or the control group at admission according to a simple randomisation using a web-based system (www.dcode.fr). Pharmaceutical va

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients born during the study period who were admitted to the NICU and stayed for at least 24 hours and with active pharmacological treatment

Exclusion criteria

Exclusion criteria: Patients admitted without pharmacological treatment or less than 24h.

Design outcomes

Primary

Measure	Time frame
Percentage of prescription errors detected by a clinical pharmacist in e-prescribing measured at the end of the study	—

Secondary

Measure	Time frame
Percentage of prescribing errors reaching the patient according to the nursing administration record measured at the end of the study	—

Countries

Spain

Contacts

Public ContactMaria Dolores Canales

mcanales@salud.madrid.org+34 675091692

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026